Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
复制标题
DOI：
10.1093/eurheartj/ehaa1007
复制
发表时间：
2021-03-31
影响因子：
39.3
通讯作者：
EMPEROR-Reduced Trial Committees and Investigators
中科院分区：
文献类型：
--
作者：
Butler J;Anker SD;Filippatos G;Khan MS;Ferreira JP;Pocock SJ;Giannetti N;Januzzi JL;Piña IL;Lam CSP;Ponikowski P;Sattar N;Verma S;Brueckmann M;Jamal W;Vedin O;Peil B;Zeller C;Zannad F;Packer M;EMPEROR-Reduced Trial Committees and Investigators
在EMPEROR-Reduced试验的次要分析中，我们试图评价恩格列净的获益是否因基线健康状况而异，以及恩格列净如何影响射血分数降低的心力衰竭患者的患者报告结局。健康状况通过堪萨斯城心肌病患者临床综合评分（KCCQ-CSS）进行评估。使用考克斯比例风险模型检查基线KCCQ-CSS（按三分位数分析）对恩格列净对主要结局影响的影响。进行应答者分析，以评估与恩格列净治疗相关的KCCQ评分改善和恶化的几率。无论基线KCCQ-CSS三分位数如何，恩格列净均降低了心血管死亡或心力衰竭住院治疗的主要结局[风险比（HR）0.83 <62.5、62.6-85.4和≥85.4分三分位数分别为HR 0.74（0.58-0.94）和HR 0.61（0.46-0.82）; P趋势= 0.10]。恩格列净改善了第3、8和12个月时的KCCQ-CSS、总症状评分和总体总分。在3个月时，恩格列净组更多患者的KCCQ-CSS改善≥5分[比值比（OR）1.20（1.05-1.37）]、10分[OR 1.26（1.10-1.44）]和15分[OR 1.29（1.12-1.48）]，较少患者的KCCQ-CSS恶化≥5分[OR 0.75（0.64-0.87）]。这些益处在8个月和12个月时持续存在，并且与其他KCCQ领域相似。在基线健康状态范围内，恩格列净可改善心血管死亡或心力衰竭住院风险。恩格列净改善了多个领域的健康状况，并且在长期随访期间维持了这种获益。URL：https://www.clinicaltrials.gov。唯一标识符：NCT 03057977。
In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagliflozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in patients with heart failure with reduced ejection fraction. Health status was assessed by the Kansas City Cardiomyopathy Questionnaires-clinical summary score (KCCQ-CSS). The influence of baseline KCCQ-CSS (analyzed by tertiles) on the effect of empagliflozin on major outcomes was examined using Cox proportional hazards models. Responder analyses were performed to assess the odds of improvement and deterioration in KCCQ scores related to treatment with empagliflozin. Empagliflozin reduced the primary outcome of cardiovascular death or heart failure hospitalization regardless of baseline KCCQ-CSS tertiles [hazard ratio (HR) 0.83 (0.68–1.02), HR 0.74 (0.58–0.94), and HR 0.61 (0.46–0.82) for <62.5, 62.6–85.4, and ≥85.4 score tertiles, respectively; P-trend = 0.10]. Empagliflozin improved KCCQ-CSS, total symptom score, and overall summary score at 3, 8, and 12 months. More patients on empagliflozin had ≥5-point [odds ratio (OR) 1.20 (1.05–1.37)], 10-point [OR 1.26 (1.10–1.44)], and 15-point [OR 1.29 (1.12–1.48)] improvement and fewer had ≥5-point [OR 0.75 (0.64–0.87)] deterioration in KCCQ-CSS at 3 months. These benefits were sustained at 8 and 12 months and were similar for other KCCQ domains. Empagliflozin improved cardiovascular death or heart failure hospitalization risk across the range of baseline health status. Empagliflozin improved health status across various domains, and this benefit was sustained during long-term follow-up. URL: https://www.clinicaltrials.gov. Unique identifier: NCT03057977.
登录
查看更多内容
影响因子：
37.8
作者：
Kosiborod, Mikhail N.;Jhund, Pardeep S.;McMurray, John J. V.
通讯作者：
McMurray, John J. V.
DOI：
10.1161/circoutcomes.115.001958
发表时间：
2015-09-01
影响因子：
6.9
作者：
Spertus, John A.;Jones, Philip G.
通讯作者：
Jones, Philip G.
DOI：
10.1007/s11936-013-0249-2
发表时间：
2013-08-01
影响因子：
--
作者：
Lewis, Eldrin F
通讯作者：
Lewis, Eldrin F
影响因子：
--
作者：
Vaishnava, Prashant;Lewis, Eldrin F
通讯作者：
Lewis, Eldrin F
影响因子：
9.7
作者：
Lewis, Eldrin F.;Claggett, Brian L.;Swedberg, Karl
通讯作者：
Swedberg, Karl